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The impact of Lithium on thyroid function
in Chinese psychiatric population
Kwan Yee Queenie Tsui
Abstract
Background: Lithium was known to cause thyroid dysfunction and most commonly subclinical hypothyroidism
(SCH). The aim of this study is to determine the prevalence of Lithium associated thyroid dysfunction and to
identify risk factors associated with development of SCH in patients receiving Lithium.
Methods: A retrospective cross-sectional study was conducted. Subjects who developed elated thyroid stimulating
hormone (TSH) were compared with those who remained euthyroid with Lithium treatment. Logistic regression
and survival analysis were applied to identify the significant factors associated with SCH.
Results: The prevalence of Lithium associated with SCH was 31.7 %. The significant risk factors associated with
increased risk of SCH included being female, higher serum Lithium level, concomitant use of Valproate Sodium and
use of antidepressant. Use of depot injection was associated with decreased risk of SCH.
Conclusions: Use of depot and avoidance of Valproate or antidepressant should be taken into account before
starting patient on Lithium treatment. Thyroxine replacement should be considered when Lithium associated SCH
was identified.
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Background
Lithium, discovered in 1817, was initially used for treat-
ing gout. Throughout years of research since its intro-
duction, Lithium has now been well established as an
effective agent for treatment in acute mania, prophylaxis
of bipolar disorder and augmentation in refractory de-
pression. Possible long term side effects included renal
insufficiency, thyroid dysfunction, persistent tremor, and
dermatologic effects of acne and alopecia [1]. Among
the possible side effects of Lithium, thyroid dysfunction
especially subclinical hypothyroidism (SCH) was a com-
mon yet often neglected one. Lithium was reported to
concentrate in thyroid gland and inhibit thyroidal iodine
uptake. It also inhibits iodotyrosine coupling, alters
thyroglobulin structure and inhibits thyroid hormone se-
cretion. Lithium inhibits synthesis and release of thyroid
hormones by stabilizing effect on thyroid microtubules,
decreasing adenylate cyclase responsiveness to TSH and
suppressing cyclic adenosine mono phosphate (c-AMP)
production. Lithium lowers de-iodination in the liver
and decreases the clearance of free T4 [2].
According to ETA Guideline, SCH was characterized by
TSH above the upper reference limit in combination with
a normal free thyroxine (T4). Clinical hypothyroidism was
characterized by TSH above the upper reference limit in
combination with low free T4. Both situations were indi-
cated by elated TSH.
The prevalence of clinical and subclinical hypothyroidism
in the general population were 0.3 and 4.3 % respectively
(NHANES III, 1988–1994). 36 % bipolar patients developed
abnormal TSH with or without T4 abnormality while on
Lithium [3]. The prevalence of clinical hypothyroidism
while on Lithium was 10.4 % [4]. The prevalence of
SCH while on Lithium was reported to be up to 20.3 %
[5]. Bocchetta et al. noted only 1 case of hyperthyroid-
ism among 150 patients on long term Lithium therapy
during a 15 year follow up, suggesting Lithium induced
hyperthyroidism was extremely rare [6]. Thus in this
study, we would focus on mainly risk factors associated
with development of elated TSH on Lithium.Correspondence: luna-1005@hotmail.com
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Methods
This study was a retrospective cross-sectional analysis of
case notes of all Chinese psychiatric patients, who were
receiving Lithium treatment and had serum thyroid func-
tion test (TFT) and Lithium level taken in the past one
year on 1st March 2014. It was conducted in the Depart-
ment of Psychiatry of Pamela Youde Nethersole Eastern
Hospital (PYNEH) in Hong Kong. The medical records of
potential study sample were retrieved and screened from
the Medical Record Office (MRO) and electronic Clinical
Management System (e-CMS) of Hospital Authority in
Hong Kong. The reference range of TSH and free T4 were
0.35–3.80mIU/L and 9.5–18.1pmol/L respectively in
PYNEH. Patients who were not from Chinese origin and
had thyroid dysfunction before starting Lithium treatment
as indicated by TFT or documented in medical notes were
excluded. Among 262 patients eligible for the study, 109
(41.6 %) patients were male and 153 (58.4 %) were female.
The study population comprised of relatively balanced
gender ratio of 1 male to 1.4 female. The mean age of the
study population was 48.57 years old with standard devi-
ation of 12.267 years.
A collection of important factors were indentified as
independent variables that might predispose to the devel-
opment of SCH in the participants, including demo-
graphic factors, clinical characteristics and characteristics
of medications prescribed. The number of months be-
tween the date of starting Lithium and development of
elated TSH would be calculated as “duration of Lithium
use”. If TSH remained normal throughout the study
period, the number of months between the dates of start-
ing Lithium till 1st March 2014 would then be calculated
as “duration of Lithium use”.
Data analysis
Comparison of demographic and clinical data between
patients with normal and elated TSH while on Lithium
treatment were done in univariate analysis. Variables
showing statistically significant difference (p < 0.05) or
marginally significant difference (0.05 ≤ p < 0.10) would
be indentified and multivariate logistic regression ana-
lysis would then applied. Variables having p < 0.05 after
multivariate logistic regression were considered as sig-
nificant. Survival analysis was further conducted to
indentify factors associated with development of elated
TSH while on Lithium treatment. Kaplan-Meier survival
curve would be plotted to give graphical representation
of the survival function. Data was analyzed through IBM
Statistical Product and Service Solution (SPSS) software
version 22.
Ethics approval
This study was approved by the Ethics Committee of
Hong Kong East Cluster of Hospital Authority (HA) and
the Chief of Service of the Department of Psychiatry of
PYNEH.
Results
Total 304 cases that were on Lithium treatment at
PYNEH on 1st March 2014 were indentified through
CDARS. Ethnicity, availability of thyroid and Lithium
monitoring in the past one year and presence of thyroid
illness before starting Lithium treatment were screened.
Total 42 cases were excluded. The overall number of pa-
tients eligible for study was 262. Among the recruited
patients, 93 (35.5 %) cases developed elated TSH, of
whom 10 (3.8 %) cases had clinical hypothyroidism and
83 (31.6 %) cases had SCH. TSH of the remaining 169
(64.5 %) patients remained non-elated while on Lithium
treatment. 10 (3.8 %) patients developed decreased TSH,
of whom 1 (0.4 %) case developed clinical hyperthyroid-
ism and 9 (3.4 %) cases developed subclinical hyperthy-
roidism. 159 (60.7 %) patients remained euthyroid
throughout the study. Figure 1 showed the forming of
the study population.
Univariate analysis was preformed between patients
with elated and non-elated TSH for demographic factors,
clinical characteristics and characteristics of medications
prescribed. Gender showed significant value of p = 0.005.
Use of Valproate Sodium (p < 0.001) and use of depot in-
jection (p = 0.008) were statistically significant and types
of Lithium taking (p = 0.073) was marginally significant.
Serum Lithium level (p = 0.001) was also statistically sig-
nificant. The univariate test results were summarized in
Table 1.
Multivariate logistic regression was then applied. Gen-
der (p = 0.001) was significantly associated with develop-
ment of elated TSH. Male gender was associated with
lower odds of development of elated TSH, in which the
odds of developing elated TSH would be 37 % of that in
female. Serum Lithium level (p = 0.007) was also found to
be associated with higher odds of development of elated
TSH. One unit (1 μmol /L = 0.001 mEq/L) increase was
associated with 0.2 % increase in the odds of developing
elated TSH (OR = 1.002). Moreover, co-administration of
depot injection with Lithium (p = 0.013) was shown to sig-
nificantly lower risk of developing elated TSH. The odds
of developing elated TSH for those on depot injection was
18.9 % of those not on depot injection (OR = 0.189).
When Valproate Sodium was prescribed with Lithium
(p < 0.001), there would be an increased risk of devel-
oping elated TSH. Patients on Valproate would have
4.522 times greater risk in having elated TSH than
those not on Valproate (OR = 4.522). The multivariate
logistic regression results were shown in Table 2.
After logistic regression analysis, survival analysis was
further conducted to explore factors which correlated to
the time to development of elated TSH. Univariate cox
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regression was applied to all the variables with results
shown in Table 3. Multivariate cox regression was then
applied to the factors having p < 0.10 in univariate cox
regression. The multivariate cox regression identified the
same four significant factors as the previous multivariate lo-
gistic regression analysis except one extra factor ‘concomi-
tant use of antidepressant’ was identified as significant in
survival analysis. The results of multivariate cox regression
were presented as follows. Firstly, gender (p = 0.008) was
statistically significant, and the hazard of male patients in
developing elated TSH was 54.1 % of that in female patients
(HR = 0.541). Secondly, serum Lithium level (p = 0.015) was
associated with higher hazard in developing elated TSH,
and one unit (1 μmol/L = 0.001 mEq/L) increase was
associated with 0.1 % raise in hazard of developing elated
TSH (HR = 1.001). Thirdly, depot injection (p = 0.046)
was shown to significantly lower the risk in developing
elated TSH while on Lithium, and the hazard of pa-
tients using depot was 30.8 % of those not on depot in-
jection (HR = 0.308). Fourthly, use of Valproate Sodium
was significant (p = 0.002), and the hazard of patients on
Valproate Sodium was 2.056 times greater in developing
elated TSH than those not taking (HR = 2.056). Lastly, as
described above, concomitant use of antidepressant with
Lithium (p = 0.04) was noted to be a significant factor, and
the hazard of patients using antidepressant in developing
elated TSH was 1.576 times greater than those not on
antidepressant treatment (HR = 1.576). The multivariate
304 patients on Lithium at PYNEH on 1st March 2014 
2 cases excluded due to non-Chinese in 
ethnicity
302 Chinese patients on Lithium  
23 cases excluded due to absence of TFT 
in past 1 year
279 Chinese patients on Lithium with TFT screening  
17 cases excluded due to pre-existing 
abnormal thyroid function or disease 
262 Chinese euthyroid patients on Lithium with TFT screening  
93 patients developed elated 
TSH  
169 patients had non-elated 
TSH
83 (31.7%) 












1 (0.4%) had 
clinical 
hyperthyroidism 
9 (3.4%) had 
subclinical 
hyperthyroidism 
Fig. 1 The forming of the study population after exclusion
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cox regression results were also shown in Table 2. In
addition, Kaplan-Meier survival curves were plotted for
the significant results identified in survival analysis as
shown in Fig. 2.
Discussion
In this study, 35.5 % patients developed elated TSH
while on Lithium treatment and it was close to the rate
(36 %) done in Pittsburgh study comprising of 143 pa-
tients [3]. Lithium induced clinical hyperthyroidism was
shown to be a rare event as only 1 out of 262 patients
developed clinical hyperthyroidism in this study.
It was found that the risk of developing SCH when on
Lithium was significantly higher in women, which was
also reported in other studies [4, 7]. Such difference was
likely due to the exacerbating effect of estradiol in
Table 1 Univariate tests for factors between patient with






Male 81 (47.9 %) 28 (30.1 %) 0.005*a










86 (50.9 %) 46 (49.5 %)
Depression/Anxiety 26 (15.4 %) 11 (11.8 %)
Mental Retardation 3 (1.8 %) 3 (3.2 %)




Personality Disorder 1 (0.6 %) 1 (1.1 %)
Mental Retardation 6 (3.5 %) 1 (1.1 %)
Substance Abuse 5 (3.0 %) 1 (1.1 %)
Autistic Spectrum
Disorder
2 (1.2 %) 1 (1.1 %)
Others 0 (0.0 %) 2 (2.1 %)
Nil 155 (91.7 %) 87 (93.5 %)
Physical Comorbidities
Hypertension 0.505a
Yes 25 (14.8 %) 11 (11.8 %)
No 144 (85.2 %) 82 (88.2 %)
Diabetes 0.911a
Yes 21 (12.4 %) 12 (13 %)
No 148 (87.6 %) 81 (87 %)
Hyperlipidaemia 0.410a
Yes 18 (10.7 %) 7 (7.5 %)




Yes 2 (1.2 %) 2 (2.2 %)
No 167 (98.8 %) 91 (97.8 %)
Types of Lithium taking 0.073**a
Lithium CR 141 (83.4 %) 69 (74.2 %)
Lithium IR 28 (16.6 %) 24 (25.8 %)
Frequency of Lithium per
day
0.311b
Once 147 (87.0 %) 75 (80.6 %)
Twice 20 (11.8 %) 17 (18.3 %)
Three times 2 (1.2 %) 1 (1.1 %)
Use of depot injection 0.008*b
Yes 22 (13.0 %) 3 (3.2 %)
Table 1 Univariate tests for factors between patient with
non-elated and elated TSH (Continued)
No 147 (87.0 %) 90 (96.8 %)
Use of oral antipsychotics 0.421a
Yes 129 (76.3 %) 75 (80.6 %)
No 40 (23.7 %) 18 (19.4 %)
Use of antidepressant 0.746a
Yes 62 (36.7 %) 36 (38.7 %)
No 107 (63.3 %) 57 (61.3 %)
Use of Benzodiazepine 0.742a
Yes 80 (47.3 %) 46 (49.5 %)
No 89 (52.7 %) 47 (50.5 %)
Use of Carbamazepine 0.669b
Yes 3 (1.8 %) 3 (3.2 %)
No 166 (98.2 %) 90 (96.8 %)
Use of Valproate Sodium < 0.001*a
Yes 18 (10.7 %) 31 (33.3 %)
No 151 (89.3 %) 62 (66.7 %)
Use of other mood
stabilizers
1.000a
Yes 5 (3.0 %) 2 (2.2 %)




Yes 77 (45.6 %) 44 (47.3 %)
No 92 (54.4 %) 49 (52.7 %)
Age, mean (SD) 48.47 (12.188) 48.76 (12.473) 0.852c
Serum Lithium Level
(μmol /L), mean (SD)
541.30 (217.701) 639.14 (212.984) 0.001*c
Dosage of Lithium (mg),
median (IQR)
800 (675–1000) 800 (600–800) 0.364d
Note: *significant p < 0.05, **marginally significant 0.05 ≤ p < 0.10, aChi-squared
test, bFisher’s exact test, cIndependent-sample-t-test, dMann-Whitney U Test,
SD Standard Deviation, IQR Interquartile Range
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women and protective effect of testosterone in men. It
has been demonstrated that estradiol would decrease
iodide uptake in thyroid follicular cells [8]. Testosterone
had also been shown to decrease thyroid enlargement
and prevent the fall in free T4 levels in rats [9].
It was demonstrated in this study that there was a
positive correlation between serum Lithium level and
risk of developing elated TSH. A few studies had also re-
ported on such finding [10, 11].
Antipsychotics were well known for their central activity
on tuberoinfundibular dopaminergic pathway. The antag-
onism of dopamine 2 receptor could increase Thyroid
Releasing Hormone stimulated TSH levels [12]. Use of
depot injection had been shown to decrease risk of devel-
oping SCH. This was probably related to more stable
plasma antipsychotics concentration with less fluctuation
when using depot rather than oral administration [13].
When Valproate Sodium was taken concomitantly
with Lithium, the risk of developing SCH would become
greater. This showed that Lithium and Valproate Sodium
had synergistic effect in inducing SCH. Valproate alone
had been proven to induce SCH by several studies [14].
Valproate had been reported to increase serum Gamma-
aminobutyric Acid (GABA) level [15]. GABA was also
shown to inhibit TSH-stimulated thyroid hormone re-
lease from the thyroid gland [16]. Another mechanism
proposed was Valproate induced SCH through blockage
of N-methyl-D-aspartate (NMDA) synaptic transmission
[17], while NMDA had been shown to increase serum
thyroid hormone level [18]. Hence, both mechanisms
would stimulate TSH release from the pituitary gland.
At last, use of antidepressant with Lithium was shown
to increase risk of developing SCH. Such increased in risk
was consistent with previous study results in which pa-
tients developed increased TSH while on Sertraline and
Desipramine [19, 20]. Though the mechanism behind
remained unclear. The possible explanation would be
serotonin increased by antidepressant when administered
in a chronic fashion induced lower plasma levels of thy-
roid hormones [21]. Thus, Lithium and antidepressant
had synergistic effect in inducing SCH and such effect was
only revealed by survival analysis when survival time was
taken into account.
For patients who were at increased risk of developing
thyroid dysfunction including being female, with per-
sonal or family history of thyroid disorders and with
positive autoimmune markers or abnormal TFT in the
initial blood taking prior to initiating Lithium, special
caution in prescription regimen to avoid further exacer-
bation or development of thyroid dysfunction should be
taken. According to this study, depot injection could be
put at a higher priority than oral administration when
antipsychotics were indicated. Simplification of regimen
should be adopted, since co-administration of Valproate
Table 2 Significant factors identified in multivariate analysis
Multivariate Logistic Regression
Factors OR (95 % CI) p
Gender (Male) 0.370 (0.202–0.679) 0.001
Serum Lithium Level 1.002 (1.001–1.003) 0.007
Use of depot injection 0.189 (0.051–0.704) 0.013
Use of Valproate Sodium 4.522 (2.179–9.381) < 0.001
Survival Analysis
Multivariate Cox Regression
Factors HR (95 % CI) p
Gender 0.541 (0.344–0.851) 0.008
Serum Lithium Level 1.001 (1.0–1.002) 0.015
Use of depot injection 0.308 (0.097–0.978) 0.046
Use of antidepressant 1.576 (1.021–2.435) 0.040
Use of Valproate Sodium 2.056 (1.311–3.224) 0.002
Note: Significant p < 0.05, OR Odds Ratio, HR Hazard Ratio, CI
Confidence Interval





Primary Psychiatric Diagnosis 0.992





Characteristics of medications prescribed
Types of Lithium taking 0.109
Frequency of Lithium per day 0.298
Serum Lithium Level 0.028*
Dosage of Lithium 0.762
Use of depot injection 0.035*
Use of oral antipsychotics 0.908
Use of antidepressant 0.067**
Use of Benzodiazepine 0.588
Use of Carbamazepine 0.221
Use of Valproate Sodium 0.001*
Use of other mood stabilizers 0.577
Use of non-psychiatric medications 0.449
Note: *Significant p < 0.05, **Marginally Significant 0.05 ≤ p < 0.10
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Fig. 2 Kaplan-Meier survival curves showing the significant results in Survival Analysis
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Sodium or antidepressant had been shown to increase
risk of developing SCH. When antidepressant was indi-
cated, it should be prescribed for short term use if pos-
sible since chronic administration would have synergistic
effect with Lithium in inducing SCH. Over-treatment
should be avoided and lowering Lithium dosage after
acute episode should be considered, since there was an
increased in risk of developing SCH for every unit in-
crease in serum Lithium level.
Discrepancy existed between different guidelines in ref-
erence to ongoing TFT monitoring in patients taking Lith-
ium. National Institute for Health and Care Excellence
(NICE), British National Formulary (BNF) and South
London & Maudsley (SLAM) recommended TFT to be
taken every 6 months while Best Practice review series
and Drugs & Therapeutic Bulletin (DTB) recommended
TFT to be taken every 12 months. Lithium had been
shown to increase antibody titers, especially, when these
antibodies had been present at the start of treatment [22].
However, among all the above guidelines, antiperoxidase
and antithyroglobulin measurements had not been in-
cluded in the initial blood tests recommended prior to
start of Lithium. Also compliance to recommended guide-
lines were still difficult when requirements were too strin-
gent, such as only 35 % of patients were compliant to the
recommended guideline of three-monthly plasma Lithium
level taking in 2013 NICE audit. Thus balance between
theoretical recommendations and practical clinical scenar-
ios remained for further discussion.
Patient’s mental state should be closely monitored
when put on Levothyroxine treatment since it had been
reported that some patients would experience mania
while on replacement therapy [23]. Levothyroxine treat-
ment should be started prior to antidepressant trial for
bipolar patients with depressive symptoms associated
with SCH since thyroxine replacement might lead to im-
provement in mood.
To our knowledge, this is the first study to have exten-
sively investigated on risk factors and predictors on Lith-
ium associated SCH in Chinese patients. Apart from
gender and age which had been widely investigated in
previous studies, other risk factors including concomi-
tant use of various psychiatric medications, comorbidi-
ties and serum Lithium level had been comprehensively
investigated in this study by both logistic regression and
survival analysis.
For the study results, consistent risk factors were
found using both logistic regression and survival analysis
meaning that these risk factors remained stable and sig-
nificant despite employment of different statistical ana-
lyses. These risk factors not only showed statistical
significance, but also gave clinical significance in further
revision of current clinical guidelines and recommended
treatment in terms of Lithium associated SCH.
There were several limitations in this study. The retro-
spective study design confined the collection of data to
be only obtained from the case records. Other factors in-
cluding infection, stress and smoking could also induce
thyroid dysfunction but such information had not been
recorded properly and consistently in case notes. An-
other limitation was this study was unable to develop
causality between exposure of the risk factors in devel-
opment of Lithium associated SCH. Besides, the severity
of psychiatric diseases, which might had an effect on the
results apart from the pharmacological action of drugs,
had not been investigated in this study. The number of
individuals having various severity levels of different psy-
chiatric diagnoses would be too small and therefore they
had been grouped together according to their mental
disorders for statistical analysis.
Further research is required to establish and investi-
gate on the effectiveness of depot in reducing develop-
ment of SCH on Lithium when compared with use of
oral antipsychotics. The effect of chronic administration
of antidepressant and Lithium should also be further ex-
plored in development of SCH. Few studies had investi-
gated on relationship with serum Lithium level and risk
of SCH and further research might be required. With re-
search in more comprehensive and deeper perspective, it
was hoped that further improvement in current Lithium
guidelines could be reached.
Conclusions
Despite various psychiatric medications had been discov-
ered and manufactured throughout the century, Lithium
remained the only drug with an established anti-suicidal
efficacy for affective disorders. It was still widely advocated
in patients with bipolar affective disorder and refractory
depression. Thyroid dysfunction complicated by Lithium
treatment had been investigated, but SCH with related
risk factors was often neglected. Use of depot and avoid-
ance of Valproate or antidepressant should be taken into
account for patients receiving Lithium treatment. Serum
Lithium level and thyroid function should be monitored
regularly, and thyroxine replacement should be considered
when Lithium associated SCH was identified. With in-
creasing evidence in harm and risk of untreated SCH, fur-
ther research and revision of current Lithium guidelines
would be required.
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